Natco Pharma files suit in Delhi High Court seeking revocation of Novo Nordisk's patent on diabetes drug semaglutide. Court issues notice, hearing set for Feb 5. Indian pharma race for generic Ozempic heats up.
Hyderabad's Natco Pharma petitions Delhi High Court to revoke Novo Nordisk's semaglutide patent. The legal battle shapes India's future weight-loss drug market as 2026 patent expiry nears. Read more.
Novo Nordisk launches oral Wegovy weight-loss drug in the US, priced at $299. The pill, approved in Dec 2025, aims to regain market share from rival Eli Lilly. UK approval expected end-2026.
Novo Nordisk expects India's obesity drug market to grow rapidly after a 37% Wegovy price cut, mirroring insulin uptake. Generic competition looms with a Rs 5000-crore opportunity.
The patent expiry of semaglutide drugs will create a massive Rs 50 billion+ revenue opportunity for generic makers in India and globally over the next 12-15 months, boosting diabetes treatment access. Read the full analysis.
Patent expiry of semaglutide drugs will create a Rs 50+ billion revenue chance for generic pharma firms in 12-15 months. Prices may drop up to 75%, boosting patient access. Read the full analysis.
The patent expiry of Novo Nordisk's blockbuster drug semaglutide (Ozempic, Wegovy) opens a massive Rs 50,000+ crore market for Indian generic drugmakers, a new report reveals.
New data shows semaglutide reduces major heart events by 20%, independent of weight loss. This breakthrough offers new hope for India's early-onset heart disease patients. Learn more.
GLP-1 weight-loss drugs, despite limited uptake, topped India's pharma sales by value in 2025. With generics and new approvals coming, 2026 promises wider access. Plus, government plans 200+ Day Care Cancer Centres. Read the full analysis.
As patents expire, Indian drugmakers like Lupin and Ajanta Pharma are forging licensing and distribution deals for GLP-1 obesity drugs. The market is set for explosive growth. Explore the key partnerships and market dynamics.
Ajanta Pharma partners with Biocon to market weight-loss drug semaglutide in 26 markets. Deal expected to add ₹200 crore sales by FY28, enhancing its branded generics focus. Read more.
India's anti-obesity market, now valued at over Rs 1,000 crore, is poised for explosive growth with new drugs and generics. Discover how AI and GLP-1 therapies are transforming healthcare.
Ajanta Pharma partners with Biocon to distribute generic semaglutide in 26 Asian and African markets. The move targets the booming GLP-1 market post-patent expiry, leveraging Ajanta's strong distribution network.
US FDA approves Novo Nordisk's daily Wegovy pill, an oral alternative to injections. Priced from $149, it offers 14% average weight loss. Details on cost, side effects, and how it compares to rivals.
New research reveals GLP-1 drugs like semaglutide offer significant heart, liver, and kidney benefits, transforming treatment for obesity-related conditions. Discover the full scope of their impact.
Emcure Pharmaceuticals launches Poviztra, a weekly semaglutide injection for weight loss, in partnership with Novo Nordisk. Priced from ₹2,200 per week, it targets India's massive obesity market.
Bangladesh's pharma firms have a 2-year head start over Indian giants like Dr Reddy's in exporting generic semaglutide. Delhi HC allows exports, but domestic sales wait until 2026. Explore the competitive landscape.
Delhi High Court rejects Novo Nordisk's patent plea on semaglutide (Ozempic/Wegovy), preventing 'evergreening'. A win for affordable generics in India, but raises concerns over non-clinical misuse of weight-loss drugs. Read more.
India & Russia sign 16 pacts, chart roadmap till 2030. Key takeaways on labour mobility, trade, defence & nuclear energy. Essential analysis for UPSC aspirants on bilateral ties, repo rate, labour codes & more.
Delhi High Court rejects Novo Nordisk's plea for interim injunction against Dr Reddy's Labs over semaglutide. Court cites 'evergreening', allows DRL to export. Key ruling for diabetes drug market.
A recent Delhi High Court order in the Novo Nordisk vs Dr Reddy's case highlights the complexities of Indian patent litigation. We examine the system's challenges and the push for specialized IP courts.
WHO releases its first global guideline on GLP-1 therapies for obesity, recommending drugs like semaglutide for adults with a BMI over 30. Learn about the impact, safety, and who can benefit.
Delhi High Court permits Dr Reddy's to export generic semaglutide, a major win for Indian drugmakers eyeing the booming anti-obesity market. Read the full analysis.
Novo Nordisk and Eli Lilly develop daily oral weight loss pills with 10-16% average weight loss in trials. Pending FDA approval, these could replace injections.
Shaily Engineering and Gland Pharma positioned to benefit from India's semaglutide gold rush as patent expiry opens market for generic weight-loss drugs. Discover how these companies are preparing.
Michelle Obama faces Ozempic rumors after revealing slimmer frame in Annie Leibovitz photoshoot. Social media erupts with speculation despite no evidence. Read the full story.
Lupin stocks trade at 21.7x P/E despite record earnings and 80 new products pipeline. Discover why this pharma giant might be undervalued and poised for next growth cycle with biosimilars and complex generics.
OneSource Pharma hikes FY28 revenue guidance to over $500 million, plans $100M expansion for weight-loss drugs like semaglutide. CEO reveals accelerated growth strategy.
Biocon's generics business surges 24% driven by weight-loss drugs liraglutide & semaglutide. CEO Siddharth Mittal reveals strategy to capture share of the booming $95 billion GLP-1 market.
In a major breakthrough for weight management, the White House has secured a deal that significantly reduces prices of popular drugs Ozempic and Wegovy, making effective weight loss treatment more accessible across India.